Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
6.66
+0.16 (2.46%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 21 employees as of December 31, 2023. The number of employees decreased by 6 or -22.22% compared to the previous year.
Employees
21
Change (1Y)
-6
Growth (1Y)
-22.22%
Revenue / Employee
$4,995
Profits / Employee
-$410,371
Market Cap
3.87M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Fresh2 Group | 75 |
Sharps Technology | 57 |
Genetic Technologies | 55 |
Sonnet BioTherapeutics Holdings | 12 |
Pasithea Therapeutics | 8 |
Chromocell Therapeutics | 8 |
Artelo Biosciences | 6 |
Lixte Biotechnology Holdings | 4 |
BDRX News
- 16 hours ago - Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out - Accesswire
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation - Accesswire
- 12 days ago - Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - Accesswire
- 14 days ago - Biodexa Announces Successful Appeal of Nasdaq Delisting - GlobeNewsWire
- 25 days ago - Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - GlobeNewsWire